Founded in 2016, Efferon specializes in developing and manufacturing advanced therapeutic devices for the treatment of sepsis and multiple organ failure syndrome through innovative extracorporeal blood purification technologies.

The company’s flagship product, Efferon LPS, a cutting-edge single-use hemoperfusion device, achieved CE mark approval under the EU Medical Device Regulation (MDR) in April 2024. Its safety and efficacy have been rigorously validated through a multicenter Randomized Clinical Trial, underscoring its impact on critical care medicine

Efferon ® LPS
Disposable Therapeutic Device for Extracorporeal Blood Adsorption

• Utilizes advanced polymeric adsorbents for the selective removal of bacterial endotoxins and cytokines.
• Designed for extracorporeal therapy to address sepsis and multiple organ failure.
• Proven to be a safe and effective method for stabilizing critically ill patients.
  

  Indications

• Sepsis of confirmed or suspected Gram-negative aetiology, including septic shock.
• Elevated endotoxin levels in the blood, are indicative of critical endotoxemia.
• Elevated cytokine levels in the blood, are associated with “cytokine storm” syndrome.
  

  Therapy Protocol

  • Day 1: First treatment session lasting 6-12 hours.
  • Day 2: Second treatment session lasting another 6-12 hours.
  • A clinical assessment should be conducted 48 hours after initiating therapy to evaluate the patient’s response and determine whether to continue treatment

Intended Use

Efferon® LPS is a single-use, non-pyrogenic, gamma-sterilized device designed for extracorporeal blood purification. It functions through the selective adsorption of lipopolysaccharides and non-selective adsorption of cytokines, myoglobin, cellular debris, and various endogenous and exogenous toxic substances, ensuring safety and reliability for critical care applications.

The device is intended for hemoperfusion within an extracorporeal circuit, either in direct hemoperfusion mode or in combination with renal replacement therapy (RRT), extracorporeal membrane oxygenation (ECMO), or cardiopulmonary bypass (CPB). By removing inflammatory mediators and endotoxins from the patient’s circulation, its timely application helps stabilize vital functions and prevents the progression of multiple organ failure in sepsis patients